VivoSeq
Other

Hypopituitarism

4

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Hypopituitarism is an early-stage landscape with 4 programs across 2 companies. The most active players are EMD Serono, Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

50/100

Attrition Rate

50/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Terminated1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism
Terminated·IInsel Gruppe AG, University Hospital Bern·N/A·NCT02360046·30 enrolled
Androgen Replacement Therapy in Women With Hypopituitarism
Completed·MMassachusetts General Hospital·N/A·NCT00027430·50 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)